Stock Analiz

Biomarin Pharmaceutical Inc. (BMRN) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Biomarin Pharmaceutical’s revenue went from $1.1B in fiscal 2016 to $3.2B in fiscal 2025, growth of about 12.5% a year.

Net income in fiscal 2025 was $349M, a net margin of 10.8%; the best year in this period was 2020 with $854M.

Over the twelve months to September 30, 2026, revenue was $3.7B and net income -$19M.

Free cash flow was $725M in fiscal 2025 and positive in 5 of the 10 years shown.

The diluted share count rose 19% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $1.1B162017: $1.3B172018: $1.5B182019: $1.7B192020: $1.9B202021: $1.8B212022: $2.1B222023: $2.4B232024: $2.9B242025: $3.2B25$3.2B
Net income
2016: -$630M162017: -$117M172018: -$77M182019: -$24M192020: $854M202021: -$64M212022: $142M222023: $168M232024: $427M242025: $349M25$349M
Free cash flow
2016: -$376M162017: -$208M172018: -$124M182019: -$97M192020: -$29M202021: $209M212022: $55M222023: $63M232024: $487M242025: $725M25$725M
EPS (diluted)
2016: $-3.81162017: $-0.67172018: $-0.44182019: $-0.13192020: $4.50202021: $-0.35212022: $0.75222023: $0.87232024: $2.21242025: $1.8025$1.80

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3.7B$3.2B$2.9B$2.4B$2.1B$1.8B$1.9B$1.7B$1.5B$1.3B$1.1B
Gross profit$2.8B$2.5B$2.3B$1.9B$1.6B$1.4B$1.3B$1.3B$1.2B$1.1B$907M
Operating income$114M$409M$484M$186M$161M-$82M-$43M-$100M-$124M-$15M-$803M
Net income-$19M$349M$427M$168M$142M-$64M$854M-$24M-$77M-$117M-$630M
EPS (diluted)$-0.10$1.80$2.21$0.87$0.75$-0.35$4.50$-0.13$-0.44$-0.67$-3.81
R&D—$922M$747M$747M$650M$629M$628M$715M$696M$611M$662M
Revenue growth—+12.9%+18.0%+15.4%+13.5%−0.8%+9.2%+14.3%+13.5%+17.6%+25.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$677M$828M$573M$159M$176M$305M$85M$48M$20M-$9M-$228M
Capital spending-$119M-$103M-$85M-$97M-$121M-$96M-$114M-$145M-$145M-$199M-$148M
Free cash flow$558M$725M$487M$63M$55M$209M-$29M-$97M-$124M-$208M-$376M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks————$0$0$50M$0$0——
Stock-based pay$220M$181M$202M$207M$196M$197M$190M$160M$149M$140M$135M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$1.6B$1.1B$1.1B$1.3B$1.0B$1.1B$754M$1.1B$1.4B$790M
Debt—$645M$638M$1.1B$1.1B$1.1B$1.1B$922M$870M$814M$661M
Equity—$6.1B$5.7B$5.0B$4.6B$4.3B$4.1B$3.1B$3.0B$2.8B$2.8B
Total assets—$7.6B$7.0B$6.8B$6.4B$6.0B$5.8B$4.7B$4.4B$4.6B$4.0B
Shares (diluted)194M197M197M192M189M183M192M179M177M174M166M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin76.0%77.7%79.7%78.0%76.0%74.5%71.8%78.9%78.9%81.6%81.2%
Operating margin3.1%12.7%17.0%7.7%7.7%-4.5%-2.3%-5.9%-8.3%-1.1%-71.9%
Net margin-0.5%10.8%15.0%6.9%6.8%-3.5%45.9%-1.4%-5.2%-8.9%-56.4%
FCF margin15.3%22.5%17.1%2.6%2.6%11.3%-1.6%-5.7%-8.3%-15.8%-33.7%
ROIC—4.4%6.1%2.7%2.7%-1.3%-0.7%-2.0%-1.7%-0.3%-17.8%
ROE—5.7%7.5%3.4%3.1%-1.5%20.8%-0.8%-2.6%-4.2%-22.8%

Frequently asked questions

What is Biomarin Pharmaceutical’s annual revenue?

$3.2B in fiscal 2025 and $3.7B over the twelve months to September 30, 2026.

How much profit does Biomarin Pharmaceutical make?

Net income was $349M in fiscal 2025 (net margin 10.8%).

Is Biomarin Pharmaceutical’s revenue growing?

Yes: revenue rose 12.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.